Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review holistic and patient-centric issues to be covered at the 4th Global NASH Congress.
Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review non-invasive testing themes to be covered at the 4th Global NASH Congress
Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to survey the agenda for the 4th Global NASH Congress.
Roger Green conducts one-on-one interviews with Stephen Harrison and Alina Allen to explore specific issues regarding new issues and insights for clinical research and drug development resulting from the work of Dr. Allen and her colleagues.
The group focuses on the patient treatment implications of being able to identify the patients who are at risk of rapid progression, particularly among those with compensated cirrhosis.
Alina Allen shares the results of her recent Clinical Gastroenterology and Hepatology paper on predictive value of MR Elastography in determining likelihood of progress for NASH patients exhibiting F1 – F3 disease and separately, those living with cirrhosis.
Alina Allen of the Mayo Clinic joins the Surfers to discuss her recent publication demonstrating that kPa scores from MR Elastography can predict the course of disease for non-cirrhotic and cirrhotic patients and consider its implications for clinical trials and every day patient treatment.
Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. This conversations starts by questioning the incremental value of ultrasound in the diagnostic process and proceeds to consider the goals of screening and two specific challenges.
Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. Listen to this conversations to consider the goals for a therapy that, in Ian’s words, “treats the patient and not the NASH.”
Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. Listen to this conversation to consider what “efficiency” means in the context of patient diagnosis and whether “less expensive” is always more efficient.
